Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an Orthotopic Mouse Model
Sébastien Taurin, Chieh-Hsiang Yang, Maria Reyes, et al.
International Journal of Gynecological Cancer (2017) Vol. 28, Iss. 1, pp. 152-160
Open Access | Times Cited: 78

Showing 1-25 of 78 citing articles:

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer
Baohui Han, Kai Li, Qiming Wang, et al.
JAMA Oncology (2018) Vol. 4, Iss. 11, pp. 1569-1569
Open Access | Times Cited: 501
Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
Guoshuang Shen, Fangchao Zheng, Dengfeng Ren, et al.
Journal of Hematology & Oncology (2018) Vol. 11, Iss. 1
Open Access | Times Cited: 493
Anlotinib: First Global Approval
Yahiya Y. Syed
Drugs (2018) Vol. 78, Iss. 10, pp. 1057-1062
Closed Access | Times Cited: 205
Emerging therapies for non-small cell lung cancer
Chao Zhang, Natasha B. Leighl, Yi‐Long Wu, et al.
Journal of Hematology & Oncology (2019) Vol. 12, Iss. 1
Open Access | Times Cited: 144
China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy
Ming Zhou, Xiaohong Chen, Hong Zhang, et al.
Cancer Communications (2019) Vol. 39, Iss. 1, pp. 1-10
Open Access | Times Cited: 84
Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma
Shenglong Li
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 64
Synergizing Success: The Role of Anlotinib Combinations in Advanced Non-Small Cell Lung Cancer Treatment
‏Helal F. Hetta, Hashim M. Aljohani, Nizar Sirag, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 4, pp. 585-585
Open Access | Times Cited: 1
Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China
Xiangyu Zhang, Liang Zeng, Yizhi Li, et al.
Cancer Immunology Immunotherapy (2021) Vol. 70, Iss. 9, pp. 2517-2528
Open Access | Times Cited: 56
Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703)
Yihebali Chi, Yongqian Shu, Yi Ba, et al.
The Oncologist (2021) Vol. 26, Iss. 10, pp. e1693-e1703
Open Access | Times Cited: 48
Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study)
Yongkun Sun, Aiping Zhou, Wen Zhang, et al.
Hepatology International (2021) Vol. 15, Iss. 3, pp. 621-629
Open Access | Times Cited: 46
A Systematic Role of Metabolomics, Metabolic Pathways, and Chemical Metabolism in Lung Cancer
Sandra Kannampuzha, Anirban Goutam Mukherjee, Uddesh Ramesh Wanjari, et al.
Vaccines (2023) Vol. 11, Iss. 2, pp. 381-381
Open Access | Times Cited: 18
A phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer
Jiayu Wang, Tao Sun, Quchang Ouyang, et al.
iScience (2023) Vol. 26, Iss. 6, pp. 106876-106876
Open Access | Times Cited: 18
<p>Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer</p>
Hongge Liang, Mengzhao Wang
Cancer Management and Research (2019) Vol. Volume 11, pp. 7707-7719
Open Access | Times Cited: 45
Anlotinib Inhibits PFKFB3-Driven Glycolysis in Myofibroblasts to Reverse Pulmonary Fibrosis
Weimou Chen, Jinming Zhang, Wenshan Zhong, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 37
Efficacy and safety of anlotinib combined with PD‐1/PD‐L1 inhibitors as second‐line and subsequent therapy in advanced small‐cell lung cancer
Lian Yu, Jianlin Xu, Rong Qiao, et al.
Cancer Medicine (2022) Vol. 12, Iss. 5, pp. 5372-5383
Open Access | Times Cited: 23
Long non-coding RNA PVT1 promotes malignancy in human endometrial carcinoma cells through negative regulation of miR-195-5p
Fanfei Kong, Jian Ma, Hui Yang, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2018) Vol. 1865, Iss. 10, pp. 1479-1490
Open Access | Times Cited: 44
<p>Anlotinib Suppresses Colorectal Cancer Proliferation and Angiogenesis via Inhibition of AKT/ERK Signaling Cascade</p>
Qian Yang, Laichao Ni, Saber İmani, et al.
Cancer Management and Research (2020) Vol. Volume 12, pp. 4937-4948
Open Access | Times Cited: 35
Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer
Nanlin Hu, Yiran Si, Jian Yue, et al.
Cancer Biology and Medicine (2021) Vol. 18, Iss. 3, pp. 849-859
Open Access | Times Cited: 29
Pembrolizumab combined with anlotinib improves therapeutic efficacy in pulmonary sarcomatoid carcinoma with TMB-H and PD-L1 expression: a case report and literature review
Shugui Wu, Shanlian Wu, Xiaohong Liao, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 13
Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer
Qi Xiong, Boyu Qin, Lingli Xin, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 24
A phase II study of anlotinib as first-line maintenance therapy for advanced ovarian cancer
Siyuan Li, Yanqin Zhang, Rong Yang, et al.
Anti-Cancer Drugs (2025)
Closed Access
Effects of anlotinib hydrochloride on the expression of immunogenic cell death-related molecules in Cal27 tongue cancer cells
Pengcheng Huang, Jitao Zhu, Lijuan Guo, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Anlotinib can overcome acquired resistance to EGFR‐TKIs via FGFR1 signaling in non‐small cell lung cancer without harboring EGFR T790M mutation
Zengzhi Lian, Wenwen Du, Yang Zhang, et al.
Thoracic Cancer (2020) Vol. 11, Iss. 7, pp. 1934-1943
Open Access | Times Cited: 26
The Suitability of FGF21 and FGF23 as New Biomarkers in Endometrial Cancer Patients
Aneta Cymbaluk‐Płoska, Paula Gargulińska, Anita Chudecka-Głaz, et al.
Diagnostics (2020) Vol. 10, Iss. 6, pp. 414-414
Open Access | Times Cited: 24
Anlotinib, Vincristine, and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy: A Two-Cohort, Phase Ib/II Trial
Jie Xu, Lu Xie, Xin Sun, et al.
The Oncologist (2021) Vol. 26, Iss. 7, pp. e1256-e1262
Open Access | Times Cited: 22
Page 1 - Next Page

Scroll to top